Harrow (HROW) Share-based Compensation (2010 - 2026)
Harrow's (HROW) quarterly Share-based Compensation came in at $3.8 million in Q1 2026, down 15.78% year-on-year from $4.6 million in Q1 2025, and up 0.97% quarter-over-quarter from $3.8 million in Q4 2025.
Harrow (HROW) Share-based Compensation (2010 - 2026) Analysis & Trends
Harrow's Share-based Compensation history runs 17 years deep, the most recent figure standing at $3.8 million for Q1 2026.
- On a quarterly basis, Share-based Compensation fell 15.78% year-over-year to $3.8 million in Q1 2026; TTM through Mar 2026 was $11.8 million, a 34.57% decrease from a year earlier, with the FY2025 full-year figure at $12.5 million, down 29.04% from the prior year.
- Share-based Compensation climbed to $3.8 million in Q1 2026 per HROW's latest filing, from $3.8 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.8 million in Q4 2022 and bottomed at $875000.0 in Q2 2025.
- The 5-year median for Share-based Compensation is $4.2 million (2024), against an average of $3.6 million.
- Across the five-year window, Share-based Compensation soared 173.57% in 2022 and slumped 79.51% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $5.8 million in 2022, then fell by 27.84% to $4.2 million in 2023, then climbed by 14.83% to $4.8 million in 2024, then dropped by 20.73% to $3.8 million in 2025, then increased by 0.97% to $3.8 million in 2026.
- Per Business Quant, the three latest HROW Share-based Compensation figures stand at $3.8 million (Q1 2026), $3.8 million (Q4 2025), and $3.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 3.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.84 Mn |
| Mar 31, 2026 | 3.84 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Sep 30, 2025 | 3.27 Mn |
| Jun 30, 2025 | 875,000.00 |
| Jun 30, 2025 | 875,000.00 |
| Mar 31, 2025 | 4.56 Mn |
| Mar 31, 2025 | 4.56 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Sep 30, 2024 | 4.39 Mn |
| Sep 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.27 Mn |
| Jun 30, 2024 | 4.27 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Dec 31, 2023 | 4.18 Mn |
| Dec 31, 2023 | 4.18 Mn |